---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-175647"
form_type: "8-K"
ticker: "SNSE"
cik: "0001829802"
company_name: "Sensei Biotherapeutics, Inc."
filed_at: "2023-06-27T23:59:59+00:00"
generated_at: "2026-06-13T16:30:47.914482+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Sensei Biotherapeutics hosts SNS-101 KOL event; no new data disclosed

## Summary
- Virtual key opinion leader event on June 27, 2023, featuring SNS-101 for solid tumors.
- Presenters include CEO John Celebi, CSO Dr. Edward van der Horst, CMO Ron Weitzman.
- Guest speaker: Dr. James Gulley, Co-Director, Center for Immuno-Oncology at NCI.
- Event is forward-looking; no clinical results or financial guidance provided.
- SNS-101 positioned as potential transformative treatment; no material milestones announced.

## SEC filing metadata
- accession: 0001193125-23-175647
- form_type: 8-K
- ticker: SNSE
- cik: 0001829802
- company_name: Sensei Biotherapeutics, Inc.
- filed_at: 2023-06-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829802/000119312523175647/0001193125-23-175647-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829802/000119312523175647/d505713d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-175647
- JSON: https://secwatch.observer/filing/0001193125-23-175647.json
- Plain text: https://secwatch.observer/filing/0001193125-23-175647.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.